CLINICAL EFFECT OF PREOPERATIVE TARGETED THERAPY ON SURGICAL OUTCOME OF STAGE Ⅱ A NON-SMALL CELL LUNG CANCER
Objective To investigate the clinical effect of preoperative targeted therapy on the surgical outcome of stageⅢ A non-small cell lung cancer (NSCLC).Methods A total of six patients with stage Ⅲ A NSCLC were enrolled.Preoperative pathological examination showed adenocarcinoma,and the detection of epidermal growth factor receptor (EGFR) gene identified mutation at site 19 or 21.All the patients were given oral EGFR tyrosine kinase inhibitor as the targeted therapy,and the course of treatment was 4-16 weeks.The patients' conditions and tumor downstaging were evaluated,and all patients underwent radical resection (pulmonary lobectomy+lymph node dissection),among whom five underwent thoracoscopic surgery and one underwent video-assisted thoracotomy.Results The time of operation was 180-260 minutes (mean (191±69) min),the intraoperative blood loss was 50-100 mL (mean (63-4-35) mL),and the length of postoperative hospital stay was 5-9 d (mean (6.3±2.1) d).All patients were improved and discharged.Pathological examination of the surgical specimens confirmed the diagnosis of primary lung adenocarcinoma (stage Ⅲ A) with extensive fibrosis of tumor tissue and interstitial fibrosis.Conclusion Preoperative targeted therapy for stage Ⅲ A NSCLC has a good clinical effect.
NETL
NSTL
万方数据
